在多发性骨髓瘤患者接受达拉图穆马布治疗的COVID-19的结果
Dian Jin1,2, Jingsong He1,3,4,5, Wenjun Wu1,3,4,5
1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cancer science
|October 26, 2023
概括
用达拉图穆马布治疗的多发性骨髓瘤患者经历了更糟糕的COVID-19结果,包括更高的肺炎,住院和严重疾病率. 达拉图穆马布暴露是这些患者严重COVID-19的危险因素.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 多发性骨髓瘤患者面临有关COVID-19不良结果的担忧,特别是那些用抗CD38抗体治疗的患者.
- COVID-19对接受达拉图姆治疗的多发性骨髓瘤患者的具体影响尚不清楚.
研究的目的:
- 评估COVID-19多发性骨髓瘤患者的临床结果,比较那些接受达拉图穆马布治疗的人与那些没有接受达拉图穆马布治疗的人.
主要方法:
- 从1036名多发性骨髓瘤患者收集的数据,其中509人被诊断为COVID-19.
- 根据COVID-19感染后6个月内的治疗情况,患者被分为达拉图巴和非达拉图巴队列.
- 倾向性得分匹配被用来比较匹配的队列 (204名患者) 之间的不良结果.
主要成果:
- 达拉图穆马布队列显示,COVID-19肺炎 (59.8%对34.3%),住院 (33.3%对11.8%) 和严重疾病 (23.5%对6.9%) 的比例明显更高.
- 通过多变量分析,Daratumumab暴露被确定为严重COVID-19疾病的独立风险因素.
- ECOG表现状况>2和慢性病是达拉图穆马布治疗患者死亡的独立风险因素.
结论:
- 暴露于达拉图穆马布的多发性骨髓瘤患者在COVID-19感染后面临更高的不良结果风险.
- 达拉图姆巴治疗可能需要对COVID-19患者进行更密切的监测和管理策略.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538